The Good, the Bad, and the Best Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Good, the Bad, and the Best Jobs
Readers provide insight into the best companies to work for as well as the ups and downs of their jobs.

Pharmaceutical Technology
Volume 32, Issue 12, pp. 74-73

Worst aspects of jobs

"Lack of acknowledgment by management of my role."

"Constraints of compliance to change."

"Constant state of not knowing how long we will be employed."

"No rewards for going the extra mile," ... "or for discovery."

"Continuously changing internal requirements."

"High work load as many projects are pushed through the pipeline."

"Turnover" ... "and frequent reorganization."

"Waiting for results from universities."

"A dull and redundant work/repeat" and "shift work."

"No appreciation that we're running a global business and need global processes."

"Regulations, regulations, regulations."

"Lulls in the work cycle."

"Having to contract to people who think they know all the answers."

"Regular panic to meet customer deadlines."

"Management does not listen to or adapt new creative ideas."

"I'm stuck in a deadbeat town somewhere in Germany."

"No improvement in quality of products."

"Working across different time zones."

"Frustrations of failed experiments."

"It's hard to see how my daily activities are advancing the larger strategy."

"Slow computer systems," and "old, unreliable equipment."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here